American Flag
LABOR DAY SALE

50% off your first year of any Quiver subscription

...

Use Promo Code:

LABOR26
Upgrade
American Flag

Insmed, Inc.

INSM Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Forecast
Insiders
Institutions
Compensation
Government
Ownership
News

Chart provided by TradingView

INSM historical prices
Income
Balance Sheet
Cash Flow
Revenue Breakdown
Congress Trading

Recent trades of INSM by members of U.S. Congress

Politician Type Traded
Josh Gottheimer House / D Sale $1,001 - $15,000 Jun 10, 2026
Gilbert Ray Cisneros, Jr. House / D Sale $1,001 - $15,000 Oct 03, 2025
Gilbert Ray Cisneros, Jr. House / D Sale $1,001 - $15,000 Sep 22, 2025
Gilbert Ray Cisneros, Jr. House / D Sale $1,001 - $15,000 Aug 08, 2025
Gilbert Ray Cisneros, Jr. House / D Sale $1,001 - $15,000 Jul 07, 2025
Josh Gottheimer House / D Purchase $1,001 - $15,000 Jun 16, 2025
Josh Gottheimer House / D Sale $1,001 - $15,000 Apr 09, 2025
Josh Gottheimer House / D Sale $1,001 - $15,000 Jun 21, 2024
Josh Gottheimer House / D Sale $1,001 - $15,000 May 28, 2024
Josh Gottheimer House / D Purchase $1,001 - $15,000 Dec 06, 2022
INSM Stock Insider Trading Activity Follow @QuiverQuant for major insider updates

---

Closing Price
Purchase
Sale
Name
Type
Shares
Price
Shares Held
Date
Reported
INSM Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
INSM Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes in INSM holdings by institutional investors

Insider Trading

Quarterly net insider trading by INSM's directors and management

* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.

About

Backtest Start Date
CAGR (Total)
Return (30d)
Return (1Y)
View Strategy Copytrade Strategy
  • 1M
  • 3M
  • 6M
  • YTD
  • 1Y
  • 2Y
  • 5Y
  • MAX

About

Backtest Start Date

Key Metrics

Return (1d)

Return (30d)

Return (1Y)

CAGR (Total)

Max Drawdown

Beta

Alpha

Sharpe Ratio

Win Rate

Average Win

Average Loss

Annual Volatility

Annual Std Dev

Information Ratio

Treynor Ratio

Total Trades

Show More
Metrics Definitions

Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.

  • Alpha

    Measures a portfolio's risk-adjusted performance against that of its benchmark

    Learn More about Alpha
  • Annual Standard Deviation

    Measures how much the portfolio's total return varies from its mean or average.

    Learn More about Annual Standard Deviation
  • Annual Volatility

    A statistical measure of the dispersion of returns for the portfolio.

    Learn More about Annual Volatility
  • Average Win

    The average return (%) for trades that resulted in a positive return.

  • Average Loss

    The average return (%) for trades that resulted in a negative return.

  • Beta

    A measure of the volatility of the portfolio compared to the market as a whole.

    Learn More about Beta
  • CAGR

    CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.

    Learn More about CAGR
  • Information Ratio

    A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.

    Learn More about Information Ratio
  • Max Drawdown

    the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.

    Learn More about Max Drawdown
  • Sharpe Ratio

    The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.

    Learn More about Sharpe Ratio
  • Total Trades

    The total number of trades made by this strategy.

  • Treynor Ratio

    Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.

    Learn More about Treynor Ratio
  • Win Rate

    The percentage of total trades that resulted in a positive return.

Subscribe to Quiver Premium for insider trading alerts

Be the first to see our newest insights and key updates across all datasets.

See Pricing
schema-2
Corporate Lobbying

Government lobbying spending instances

  • $10,000 Jul 20, 2026 Issue: Health Issues Medicare/Medicaid
  • $20,000 Jul 19, 2026 Issue: Trade (domestic/foreign)
  • $10,000 Apr 20, 2026 Issue: Health Issues Medicare/Medicaid
  • $10,000 Jan 20, 2026 Issue: Health Issues Medicare/Medicaid
  • $10,000 Oct 20, 2025 Issue: Health Issues Medicare/Medicaid
  • $10,000 Jul 14, 2025 Issue: Health Issues Medicare/Medicaid
  • $50,000 Apr 18, 2019 Issue: Health Issues
  • $50,000 Jan 18, 2019 Issue: Health Issues
  • $50,000 Oct 16, 2018 Issue: Health Issues
  • $50,000 Jul 19, 2018 Issue: Health Issues
  • $50,000 Apr 19, 2018 Issue: Health Issues
  • $22,500 Jul 20, 2011 Issue: Pharmacy
  • $22,500 Apr 11, 2011 Issue: Pharmacy
  • $22,500 Jan 17, 2011 Issue: Pharmacy
  • $22,500 Oct 12, 2010 Issue: Pharmacy
  • $22,500 Jul 20, 2010 Issue: Pharmacy
  • $22,500 May 27, 2010 Issue: Pharmacy
  • $22,500 Jan 14, 2010 Issue: Pharmacy
  • $22,500 Oct 20, 2009 Issue: Pharmacy
  • $22,500 Jul 15, 2009 Issue: Pharmacy
  • $22,500 Jul 15, 2009 Issue: Pharmacy
  • $22,500 Oct 31, 2008 Issue: Pharmacy
  • $22,500 Jul 08, 2008 Issue: Pharmacy
  • $22,500 Apr 15, 2008 Issue: Pharmacy
  • $22,500 Apr 13, 2008 Issue: Pharmacy
  • $140,000 Feb 01, 2007 Issue: Health Issues
  • $160,000 Aug 08, 2006 Issue: Health Issues
  • $40,000 Feb 13, 2006 Issue: Health Issues
Revolving Door

Former government officials who have lobbied for INSM

10 former government officials from 8 congressional offices at 3 lobbying firms have lobbied for INSM, most recently Jul 20, 2026.

  • Lamar Alexander
    Brett Meeks Senate Deputy Health Policy Director, Senate Committee on Health, Education, Labor and Pensions; Deputy Press Secretary, Office of Senator Lamar Alexander Formerly with Lamar Alexander · JEFFREY J. KIMBELL & ASSOCIATES, INC. · Jul 20, 2026
  • Marsha Blackburn
    Keith Studdard House Legislative Director, Rep. Marsha Blackburn Formerly with Marsha Blackburn · JEFFREY J. KIMBELL & ASSOCIATES, INC. · Jul 20, 2026
  • Lamar Alexander
    John Herzog Senate Health Aide, Sen. Lamar Alexander; Special Assistant to the Assistant to the President for Legislative Affairs, Executive Office of the President Formerly with Lamar Alexander · JEFFREY J. KIMBELL & ASSOCIATES, INC. · Jul 20, 2026
  • John Cornyn
    Laura Kemper Senate Counsel, Sen. John Cornyn; Deputy Assistant Secretary for Legislation, U.S. Department of Health and Human Services; Counselor to the Secretary, U.S. Department of Health and Human Services Formerly with John Cornyn · JEFFREY J. KIMBELL & ASSOCIATES, INC. · Jul 20, 2026
  • Mike Kelly
    John Ray House Legislative Assistant, Rep. Mike Kelly Formerly with Mike Kelly · JEFFREY J. KIMBELL & ASSOCIATES, INC. · Jul 20, 2026
  • Cathy McMorris Rodgers
    Kristin Fritsch House Legislative Assistant, Office of Congresswoman Cathy McMorris Rodgers; Senior Legislative Assistant, Office of Congresswoman Cathy McMorris Rodgers; Professional Staff Member House Committee on Energy and Commerce Formerly with Cathy McMorris Rodgers · JEFFREY J. KIMBELL & ASSOCIATES, INC. · Jul 20, 2026
  • Jon C. Porter
    Alanna Temme House Legislative Director, U.S. Representative Jon Porter Formerly with Jon C. Porter · LMH STRATEGIC SOLUTIONS · Jul 19, 2026
  • Mike Ferguson
    Chris Jones House New Chief of Staff, Rep. Mike Ferguson; 2001-2009; Deputy Chief of Staff, Rep. David McIntosh, 1995-2001; Communications Director, House Government Reform and Oversight Subcommittee, 1996-2001; Press Secretary, Rep. John Myers, 1994-1995. Formerly with Mike Ferguson · BAKER & HOSTETLER LLP · Apr 20, 2018
See all 10 on the Revolving Door dashboard
Corporate Lobbying

INSM Estimated quarterly lobbying spending

Revenue Breakdown

INSM Revenue by Segment or Geography

By Segment
By Geography
INSM Income Statement
INSM Balance Sheet
INSM Cash Flow
U.S. Patents

New INSM patent grants

  • Patent Title: Linear dipeptidyl peptidase 1 inhibitors and uses thereof Jul. 14, 2026
  • Patent Title: Methods for treating pulmonary non-tuberculous mycobacterial infections May. 05, 2026
  • Patent Title: Large-scale manufacturing methods for aminoglycosides Jan. 13, 2026
  • Patent Title: Reversible dpp1 inhibitors and uses thereof Nov. 25, 2025
  • Patent Title: Methods for treating pulmonary non-tuberculous mycobacterial infections Aug. 05, 2025
  • Patent Title: Methods for continuous manufacture of liposomal drug products May. 06, 2025
  • Patent Title: Dry powder compositions of treprostinil prodrugs and methods of use thereof Jan. 21, 2025
  • Patent Title: Methods for treating pulmonary non-tuberculous mycobacterial infections Dec. 17, 2024
  • Patent Title: Methods for treating pulmonary non-tuberculous mycobacterial infections Dec. 17, 2024
  • Patent Title: Deimmunized lysostaphin and methods of use Oct. 01, 2024
  • Patent Title: Methods for treating pulmonary non-tuberculous mycobacterial infections Jun. 25, 2024
  • Patent Title: Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis Jun. 04, 2024
  • Patent Title: Lipo-glycopeptide cleavable derivatives and uses thereof Jan. 02, 2024
  • Patent Title: Prostacyclin compounds, compositions and methods of use thereof Oct. 24, 2023
  • Patent Title: Dry powder compositions of treprostinil prodrugs and methods of use thereof Sep. 19, 2023
  • Patent Title: Antibodies and methods of making same May. 16, 2023
  • Patent Title: Methods for continuous manufacture of liposomal drug products Feb. 07, 2023
  • Patent Title: Dry powder compositions of treprostinil prodrugs and methods of use thereof Oct. 04, 2022
  • Patent Title: Methods for treating pulmonary non-tuberculous mycobacterial infections Sep. 20, 2022
  • Patent Title: Methods for treating pulmonary non-tuberculous mycobacterial infections Jul. 26, 2022
  • Patent Title: Methods of manufacturing treprostinil and treprostinil derivative prodrugs Oct. 19, 2021
  • Patent Title: Lipo-glycopeptide cleavable derivatives and uses thereof Jul. 27, 2021
  • Patent Title: Prostacyclin compounds, compositions and methods of use thereof May. 04, 2021
  • Patent Title: Methods for treating pulmonary non-tuberculous mycobacterial infections Nov. 10, 2020
  • Patent Title: Methods for treating pulmonary non-tuberculous mycobacterial infections Aug. 25, 2020
  • Patent Title: Compositions of multicationic drugs for reducing interactions with polyanionic biomolecules and methods of use thereof Mar. 27, 2018
  • Patent Title: Methods for treating pulmonary non-tuberculous mycobacterial infections Feb. 20, 2018
  • Patent Title: Sustained release of antiinfectives Nov. 28, 2017
  • Patent Title: Method of treating pulmonary disorders with liposomal amikacin formulations Aug. 22, 2017
  • Patent Title: Methods of treating pulmonary disorders with liposomal amikacin formulations Aug. 08, 2017
  • Patent Title: Systems for treating pulmonary infections Feb. 14, 2017
  • Patent Title: Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof Jan. 24, 2017
  • Patent Title: Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof Jan. 24, 2017
  • Patent Title: Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof Dec. 06, 2016
  • Patent Title: Prostacyclin compounds, compositions and methods of use thereof Oct. 18, 2016
  • Patent Title: Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof Aug. 02, 2016
  • Patent Title: Method for treating pulmonary disorders with liposomal amikacin formulations May. 10, 2016
  • Patent Title: Prostacyclin compounds, compositions and methods of use thereof Feb. 09, 2016
  • Patent Title: Platinum aggregates and process for producing the same Nov. 17, 2015
  • Patent Title: Method of treating pulmonary disorders with liposomal amikacin formulations Sep. 01, 2015
  • Patent Title: Methods of treating pulmonary disorders with liposomal amikacin formulations Aug. 25, 2015
  • Patent Title: Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally Aug. 18, 2015
  • Patent Title: Sustained release of antiinfectives Aug. 12, 2014
  • Patent Title: Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof Mar. 25, 2014
  • Patent Title: Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof Mar. 18, 2014
  • Patent Title: Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof Mar. 18, 2014
  • Patent Title: Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof Feb. 04, 2014
  • Patent Title: Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof Jan. 21, 2014
  • Patent Title: Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof Jul. 24, 2012
  • Patent Title: Purified rhigf-i/rhigfbp-3 complexes and their method of manufacture Jun. 28, 2011
Government Contracts

Federal grants, loans, and purchases

Government Contracts

Estimated quarterly amount awarded to INSM from public contracts

INSM News

Recent insights relating to INSM

CNBC Recommendations

Recent picks made for INSM stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in INSM

INSM Analyst Ratings

INSM Stock Forecasts
...

  • ... Highest Price Target
  • ... Median Price Target
  • ... Lowest Price Target
INSM Analyst Forecasts
Analyst
Firm
Current
Previous
Date
Frequently Asked Questions
  • Is $INSM stock a Buy, Sell, or Hold?

  • What is the price target for $INSM stock?

* Analyst consensus is not financial advice. Please see our data disclaimers .

INSM Top Shareholders
Shareholder
Shares Held
INSM Options Owners
Shareholder
Security
Underlying Shares
Frequently Asked Questions
  • Who owns $INSM stock?

  • Who owns the most shares of $INSM stock?

  • What funds own $INSM stock?

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

INSM Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view INSM Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
About INSM

Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.

  • Address Bridgewater, NJ
  • Market Cap 26.4 billion
  • Employees 1,664
  • Industrial Classification Pharmaceutical Preparations

Insmed, Inc. (INSM) Historical Stock Prices

Insmed, Inc. (INSM) closed at $120.82 on September 22, 2026. Over the past year its adjusted close ranged from $91.88 to $211.41. Daily prices go back to January 2, 2014, 3,198 trading days in all.

  • 1 month-3.94%
  • 3 months+18.28%
  • Year to date-30.58%
  • 1 year-16.69%
  • 3 years+361.67%
  • 5 years+338.07%
  • Max+604.90%
See every congressional and insider trade on the INSM price chart

Quiver Premium charts INSM's full daily history since 2014 with each congressional purchase and sale and every open-market insider purchase marked on the price line, with hover details for each trade.

Upgrade to Premium

Last 12 months, newest first

Access Raw Data Daily prices since 2014 for every ticker, through the Quiver API
DateOpenHighLowCloseAdj. CloseVolume
Sep 22, 2026 121.00 122.48 119.09 120.82 120.82 2,405,270
Sep 21, 2026 123.06 124.48 120.92 121.00 121.00 1,812,278
Sep 18, 2026 123.89 124.11 119.32 120.00 120.00 3,445,007
Sep 17, 2026 124.16 127.40 122.88 123.98 123.98 1,592,254
Sep 16, 2026 120.00 124.41 119.55 122.58 122.58 1,434,017
Sep 15, 2026 126.10 126.10 118.34 119.92 119.92 3,364,508
Sep 14, 2026 129.50 130.78 124.58 125.30 125.30 1,610,741
Sep 11, 2026 127.98 130.25 126.52 129.41 129.41 1,698,268
Sep 10, 2026 127.22 128.85 124.29 127.28 127.28 2,594,791
Sep 9, 2026 124.00 130.83 121.03 128.80 128.80 2,841,960
Sep 8, 2026 124.78 127.42 121.38 124.89 124.89 1,605,099
Sep 4, 2026 126.00 128.24 125.62 126.29 126.29 1,802,693
Sep 3, 2026 126.70 127.09 124.05 126.68 126.68 1,885,698
Sep 2, 2026 121.11 126.79 121.11 126.63 126.63 1,998,834
Sep 1, 2026 121.95 122.19 119.52 121.51 121.51 1,419,286
Aug 31, 2026 118.68 122.71 117.51 121.82 121.82 2,390,325
Aug 28, 2026 120.11 120.66 117.15 118.54 118.54 1,977,867
Aug 27, 2026 124.67 126.10 121.21 121.39 121.39 1,056,260
Aug 26, 2026 122.89 125.59 121.64 124.39 124.39 1,979,984
Aug 25, 2026 124.65 127.18 122.86 123.89 123.89 2,373,321
Aug 24, 2026 125.03 126.11 122.83 123.98 123.98 1,341,042
Aug 21, 2026 125.22 127.20 124.82 125.77 125.77 1,124,491
Aug 20, 2026 128.36 130.27 124.60 125.08 125.08 1,761,850
Aug 19, 2026 129.85 131.10 127.42 130.66 130.66 1,493,674
Aug 18, 2026 128.07 128.93 126.39 128.46 128.46 1,274,119
Aug 17, 2026 124.71 128.46 124.70 128.32 128.32 1,899,670
Aug 14, 2026 125.67 126.84 122.21 123.74 123.74 1,957,324
Aug 13, 2026 132.50 133.16 126.13 126.33 126.33 2,479,563
Aug 12, 2026 132.31 135.26 130.80 132.28 132.28 1,563,224
Aug 11, 2026 134.55 135.30 131.67 132.57 132.57 2,728,711
Aug 10, 2026 129.98 135.50 129.50 134.75 134.75 3,630,056
Aug 7, 2026 134.99 135.49 126.44 131.10 131.10 4,904,624
Aug 6, 2026 128.22 137.70 126.15 132.55 132.55 12,036,146
Aug 5, 2026 99.16 100.95 98.64 99.02 99.02 4,899,602
Aug 4, 2026 98.97 99.48 97.86 98.75 98.75 4,290,804
Aug 3, 2026 98.20 100.00 96.42 98.45 98.45 3,546,860
Jul 31, 2026 101.25 101.91 97.05 98.60 98.60 2,902,595
Jul 30, 2026 101.63 102.10 99.03 101.49 101.49 3,363,495
Jul 29, 2026 103.98 106.26 102.81 103.12 103.12 2,195,533
Jul 28, 2026 104.73 105.76 103.18 104.13 104.13 1,945,719
Jul 27, 2026 106.93 107.37 104.50 104.73 104.73 1,899,713
Jul 24, 2026 106.49 108.27 105.77 106.92 106.92 1,908,298
Jul 23, 2026 105.80 107.88 105.09 107.41 107.41 1,752,962
Jul 22, 2026 109.47 109.99 106.12 106.64 106.64 1,771,277
Jul 21, 2026 107.87 109.42 106.41 108.62 108.62 2,447,392
Jul 20, 2026 108.24 109.80 106.63 107.02 107.02 2,015,930
Jul 17, 2026 105.20 110.58 105.20 108.32 108.32 2,002,884
Jul 16, 2026 109.93 110.30 105.07 107.46 107.46 2,754,212
Jul 15, 2026 111.00 111.60 108.34 109.81 109.81 2,116,813
Jul 14, 2026 109.14 110.67 107.33 110.11 110.11 1,848,330
Jul 13, 2026 114.25 115.55 108.02 109.14 109.14 2,825,240
Jul 10, 2026 118.09 118.94 112.80 115.61 115.61 2,931,618
Jul 9, 2026 116.44 119.54 116.01 118.26 118.26 3,167,091
Jul 8, 2026 111.92 116.98 111.01 116.53 116.53 2,835,056
Jul 7, 2026 113.21 114.69 111.47 112.84 112.84 1,674,721
Jul 6, 2026 110.60 112.57 108.55 111.54 111.54 2,232,435
Jul 2, 2026 107.50 111.92 107.06 111.60 111.60 2,771,287
Jul 1, 2026 107.68 109.19 106.01 107.00 107.00 2,398,071
Jun 30, 2026 105.84 108.67 104.64 106.62 106.62 3,358,466
Jun 29, 2026 105.36 106.39 103.08 104.74 104.74 2,747,688
Jun 26, 2026 105.11 108.14 102.59 103.38 103.38 6,259,750
Jun 25, 2026 103.00 107.49 101.67 104.47 104.47 4,423,498
Jun 24, 2026 103.40 107.20 102.31 103.46 103.46 3,136,887
Jun 23, 2026 98.84 103.15 97.60 102.15 102.15 4,199,730
Jun 22, 2026 95.82 99.88 95.27 98.61 98.61 4,257,431
Jun 18, 2026 100.11 100.25 94.00 95.80 95.80 23,379,307
Jun 17, 2026 95.18 99.15 94.22 98.45 98.45 3,472,922
Jun 16, 2026 97.50 98.10 93.92 95.52 95.52 3,423,653
Jun 15, 2026 98.85 100.17 97.03 97.46 97.46 3,788,821
Jun 12, 2026 95.12 98.51 93.92 97.85 97.85 4,529,094
Jun 11, 2026 92.30 98.18 91.37 96.72 96.72 5,105,563
Jun 10, 2026 98.28 99.25 90.39 91.88 91.88 5,425,643
Jun 9, 2026 95.75 99.55 95.43 99.04 99.04 4,240,892
Jun 8, 2026 94.45 96.77 92.07 94.17 94.17 5,010,375
Jun 5, 2026 103.78 105.00 92.81 94.22 94.22 7,956,669
Jun 4, 2026 103.39 105.29 102.89 104.92 104.92 1,849,295
Jun 3, 2026 102.27 105.20 101.73 103.86 103.86 2,978,436
Jun 2, 2026 104.09 104.45 100.56 103.73 103.73 2,406,468
Jun 1, 2026 106.09 106.79 102.81 106.03 106.03 3,357,738
May 29, 2026 107.85 108.45 106.26 106.91 106.91 4,534,777
May 28, 2026 106.90 109.95 106.10 108.37 108.37 2,231,123
May 27, 2026 107.80 109.78 106.04 106.40 106.40 3,094,620
May 26, 2026 107.82 109.74 105.00 108.87 108.87 2,273,664
May 22, 2026 108.47 110.83 106.20 106.24 106.24 2,432,892
May 21, 2026 107.55 110.95 106.56 109.53 109.53 3,689,970
May 20, 2026 108.67 109.96 106.70 107.91 107.91 2,989,433
May 19, 2026 107.81 109.75 105.01 107.41 107.41 3,647,485
May 18, 2026 107.36 107.74 104.48 107.15 107.15 3,834,611
May 15, 2026 114.30 114.51 108.22 109.14 109.14 3,688,412
May 14, 2026 117.53 119.12 114.88 115.62 115.62 2,761,456
May 13, 2026 117.50 122.94 112.00 117.99 117.99 6,728,279
May 12, 2026 103.65 117.63 103.46 116.00 116.00 8,274,773
May 11, 2026 100.00 108.20 98.90 103.89 103.89 7,898,445
May 8, 2026 108.01 108.63 98.98 101.35 101.35 8,588,262
May 7, 2026 116.91 125.36 103.50 105.00 105.00 13,718,250
May 6, 2026 138.46 142.58 136.73 137.09 137.09 2,302,230
May 5, 2026 140.86 142.90 138.41 139.44 139.44 1,238,324
May 4, 2026 133.88 141.28 133.46 140.01 140.01 1,881,668
May 1, 2026 135.65 137.62 132.39 133.26 133.26 1,562,478
Apr 30, 2026 136.00 137.22 134.94 136.33 136.33 1,336,985
Apr 29, 2026 134.42 136.98 132.77 135.03 135.03 1,487,751
Apr 28, 2026 136.53 138.79 132.57 134.94 134.94 1,357,357
Apr 27, 2026 135.58 139.54 135.18 135.98 135.98 1,116,792
Apr 24, 2026 142.29 143.27 134.59 135.17 135.17 2,501,086
Apr 23, 2026 144.48 145.43 142.06 143.83 143.83 1,152,462
Apr 22, 2026 142.39 145.32 141.43 144.48 144.48 1,820,109
Apr 21, 2026 142.42 144.07 139.59 140.98 140.98 1,591,216
Apr 20, 2026 143.30 144.06 140.65 142.82 142.82 1,071,009
Apr 17, 2026 144.25 145.62 143.28 144.48 144.48 2,048,533
Apr 16, 2026 146.02 146.18 142.03 142.79 142.79 2,160,900
Apr 15, 2026 154.57 154.58 146.25 146.74 146.74 2,229,207
Apr 14, 2026 152.21 153.87 150.93 153.40 153.40 1,309,602
Apr 13, 2026 154.81 156.64 148.51 151.14 151.14 2,079,582
Apr 10, 2026 159.59 160.21 152.99 154.81 154.81 1,827,128
Apr 9, 2026 159.15 160.49 157.75 159.59 159.59 1,564,153
Apr 8, 2026 162.95 163.03 154.73 160.18 160.18 3,356,064
Apr 7, 2026 162.82 164.03 159.53 163.03 163.03 1,352,168
Apr 6, 2026 161.69 166.19 161.32 163.81 163.81 1,852,747
Apr 2, 2026 161.51 164.53 157.52 162.43 162.43 1,809,386
Apr 1, 2026 164.49 166.00 161.73 164.86 164.86 2,852,281
Mar 31, 2026 153.95 164.22 153.95 163.52 163.52 3,673,904
Mar 30, 2026 150.98 155.20 149.35 153.32 153.32 4,959,047
Mar 27, 2026 147.98 149.20 142.59 145.30 145.30 3,402,260
Mar 26, 2026 148.45 149.88 146.26 147.60 147.60 2,587,416
Mar 25, 2026 140.00 148.85 139.00 148.31 148.31 1,987,371
Mar 24, 2026 144.42 145.52 137.19 139.14 139.14 2,817,408
Mar 23, 2026 147.12 149.76 141.64 143.98 143.98 4,079,400
Mar 20, 2026 142.63 143.60 135.73 136.00 136.00 4,561,590
Mar 19, 2026 144.01 144.88 141.80 144.00 144.00 1,952,610
Mar 18, 2026 143.92 145.09 141.44 142.70 142.70 2,002,285
Mar 17, 2026 144.50 147.38 143.59 143.93 143.93 2,207,941
Mar 16, 2026 141.46 145.76 141.43 144.60 144.60 1,865,407
Mar 13, 2026 140.66 141.78 138.01 139.50 139.50 1,480,891
Mar 12, 2026 138.54 139.97 135.73 139.52 139.52 2,157,243
Mar 11, 2026 143.02 144.35 139.05 139.40 139.40 1,292,644
Mar 10, 2026 142.84 145.64 142.84 143.85 143.85 1,147,844
Mar 9, 2026 139.68 143.74 138.82 143.13 143.13 1,802,049
Mar 6, 2026 142.84 144.24 139.89 140.13 140.13 2,487,053
Mar 5, 2026 148.04 148.07 142.04 143.57 143.57 2,269,846
Mar 4, 2026 146.74 150.27 146.73 149.88 149.88 2,016,270
Mar 3, 2026 145.83 148.31 143.76 147.00 147.00 1,937,852
Mar 2, 2026 147.10 148.87 145.00 146.32 146.32 2,670,172
Feb 27, 2026 150.00 151.11 147.57 149.33 149.33 2,716,543
Feb 26, 2026 147.00 150.56 146.41 150.00 150.00 2,212,455
Feb 25, 2026 159.74 161.13 148.24 148.61 148.61 3,209,239
Feb 24, 2026 156.00 160.09 152.89 158.62 158.62 1,792,007
Feb 23, 2026 163.60 167.00 157.71 159.03 159.03 2,171,208
Feb 20, 2026 158.39 167.37 157.77 164.91 164.91 4,138,223
Feb 19, 2026 153.78 163.14 147.26 161.00 161.00 4,932,523
Feb 18, 2026 149.92 154.16 149.56 151.11 151.11 2,227,617
Feb 17, 2026 147.93 152.35 147.93 150.52 150.52 1,633,900
Feb 13, 2026 147.24 152.19 146.09 148.75 148.75 2,197,743
Feb 12, 2026 148.55 148.75 142.99 146.17 146.17 2,706,830
Feb 11, 2026 149.49 149.83 145.36 148.43 148.43 1,496,178
Feb 10, 2026 149.77 151.17 147.63 148.55 148.55 2,259,345
Feb 9, 2026 148.83 150.60 146.40 149.54 149.54 2,044,878
Feb 6, 2026 153.06 155.79 149.34 149.86 149.86 2,629,705
Feb 5, 2026 152.44 156.52 150.34 151.03 151.03 1,882,505
Feb 4, 2026 157.10 157.90 150.79 152.44 152.44 1,794,603
Feb 3, 2026 153.35 158.98 152.73 157.16 157.16 2,484,345
Feb 2, 2026 156.63 156.86 150.79 153.98 153.98 2,614,021
Jan 30, 2026 157.19 159.49 154.48 156.87 156.87 2,686,483
Jan 29, 2026 154.48 159.89 154.48 157.82 157.82 1,981,864
Jan 28, 2026 162.42 164.23 155.68 155.89 155.89 1,732,873
Jan 27, 2026 161.15 165.47 161.13 162.64 162.64 1,682,195
Jan 26, 2026 154.63 160.33 153.09 159.72 159.72 2,282,595
Jan 23, 2026 160.02 160.07 154.23 156.21 156.21 2,506,239
Jan 22, 2026 156.66 160.95 153.19 160.39 160.39 2,702,466
Jan 21, 2026 163.00 163.96 156.08 156.32 156.32 2,940,941
Jan 20, 2026 158.45 164.62 156.01 163.51 163.51 2,656,976
Jan 16, 2026 160.35 163.98 158.39 161.42 161.42 3,676,502
Jan 15, 2026 163.00 164.00 158.42 159.27 159.27 2,314,258
Jan 14, 2026 163.83 164.96 160.45 163.46 163.46 2,623,466
Jan 13, 2026 170.00 170.45 162.30 163.72 163.72 3,741,589
Jan 12, 2026 174.86 175.12 165.28 167.72 167.72 4,123,627
Jan 9, 2026 185.02 186.19 169.00 175.97 175.97 5,433,426
Jan 8, 2026 174.17 175.00 168.01 170.27 170.27 2,589,004
Jan 7, 2026 175.07 178.75 173.34 176.00 176.00 2,179,972
Jan 6, 2026 173.33 175.41 170.94 175.07 175.07 1,850,230
Jan 5, 2026 176.12 176.12 167.39 175.20 175.20 2,261,911
Jan 2, 2026 175.79 177.90 173.55 177.12 177.12 1,831,472
Dec 31, 2025 174.18 175.25 173.24 174.04 174.04 1,781,389
Dec 30, 2025 175.79 176.51 173.48 174.09 174.09 1,651,368
Dec 29, 2025 177.61 178.52 175.37 176.34 176.34 2,481,754
Dec 26, 2025 178.90 179.44 176.67 177.88 177.88 1,035,879
Dec 24, 2025 175.50 178.10 175.00 177.42 177.42 747,292
Dec 23, 2025 174.17 177.60 172.65 176.77 176.77 1,619,148
Dec 22, 2025 177.58 179.32 174.00 175.76 175.76 2,745,046
Dec 19, 2025 168.30 178.21 166.71 174.84 174.84 19,087,989
Dec 18, 2025 167.75 172.31 161.02 166.55 166.55 13,491,281
Dec 17, 2025 200.05 205.23 198.07 198.46 198.46 4,476,661
Dec 16, 2025 195.39 204.04 192.50 200.67 200.67 3,647,827
Dec 15, 2025 197.23 201.13 194.75 196.92 196.92 4,146,744
Dec 12, 2025 195.00 198.13 191.74 197.01 197.01 1,898,089
Dec 11, 2025 190.24 195.36 189.77 195.24 195.24 2,282,839
Dec 10, 2025 194.87 197.50 189.59 189.85 189.85 2,484,801
Dec 9, 2025 194.50 198.40 193.29 194.17 194.17 2,347,467
Dec 8, 2025 206.69 206.69 195.54 196.55 196.55 3,501,651
Dec 5, 2025 204.68 206.56 203.15 204.00 204.00 2,160,144
Dec 4, 2025 207.58 208.81 202.68 205.04 205.04 1,861,198
Dec 3, 2025 206.60 207.60 203.33 206.78 206.78 2,544,385
Dec 2, 2025 212.08 212.75 206.10 206.60 206.60 1,383,927
Dec 1, 2025 206.80 212.58 205.00 211.41 211.41 1,868,208
Nov 28, 2025 206.22 208.05 202.88 207.77 207.77 1,052,640
Nov 26, 2025 208.49 209.00 202.27 204.51 204.51 2,045,039
Nov 25, 2025 206.93 209.77 205.23 209.02 209.02 2,196,814
Nov 24, 2025 202.43 208.72 199.52 206.93 206.93 15,708,829
Nov 21, 2025 199.10 201.44 194.65 198.76 198.76 2,629,810
Nov 20, 2025 204.35 208.00 199.00 199.64 199.64 2,333,221
Nov 19, 2025 201.08 205.11 200.19 203.56 203.56 1,581,719
Nov 18, 2025 195.80 203.65 195.51 201.62 201.62 2,412,985
Nov 17, 2025 192.58 197.88 191.82 197.40 197.40 1,884,474
Nov 14, 2025 188.09 197.44 187.55 193.22 193.22 2,551,474
Nov 13, 2025 193.78 196.47 190.58 190.96 190.96 2,163,757
Nov 12, 2025 192.61 196.33 191.90 194.39 194.39 1,602,811
Nov 11, 2025 189.93 193.93 187.61 193.69 193.69 1,762,186
Nov 10, 2025 189.67 192.39 185.69 191.92 191.92 2,080,777
Nov 7, 2025 184.10 189.82 182.53 189.70 189.70 2,191,698
Nov 6, 2025 186.77 188.45 183.81 185.68 185.68 1,857,748
Nov 5, 2025 182.92 189.31 182.09 186.88 186.88 1,635,247
Nov 4, 2025 185.28 187.88 182.58 182.77 182.77 2,052,847
Nov 3, 2025 187.90 188.56 178.76 186.23 186.23 3,081,570
Oct 31, 2025 194.57 197.08 187.02 189.60 189.60 3,156,070
Oct 30, 2025 171.26 194.70 167.00 194.22 194.22 6,733,684
Oct 29, 2025 166.48 167.78 163.82 166.95 166.95 2,798,308
Oct 28, 2025 164.02 167.07 163.11 165.29 165.29 1,172,542
Oct 27, 2025 162.05 164.13 160.53 164.02 164.02 1,465,631
Oct 24, 2025 161.84 162.29 158.81 159.66 159.66 1,111,096
Oct 23, 2025 159.41 160.30 154.79 160.12 160.12 2,442,223
Oct 22, 2025 165.90 166.62 159.65 160.40 160.40 2,431,482
Oct 21, 2025 166.90 168.09 162.80 165.31 165.31 1,732,892
Oct 20, 2025 167.17 168.22 163.42 167.91 167.91 1,388,064
Oct 17, 2025 163.80 166.04 161.19 165.76 165.76 1,391,513
Oct 16, 2025 163.95 166.40 162.37 163.19 163.19 1,907,267
Oct 15, 2025 162.20 165.76 161.65 163.54 163.54 2,188,223
Oct 14, 2025 163.99 164.34 161.34 161.38 161.38 1,069,145
Oct 13, 2025 163.22 166.44 162.08 163.94 163.94 1,464,597
Oct 10, 2025 164.11 164.23 161.31 162.33 162.33 2,032,527
Oct 9, 2025 162.16 164.58 161.03 164.40 164.40 1,411,667
Oct 8, 2025 161.90 163.22 159.78 161.81 161.81 1,954,461
Oct 7, 2025 156.87 162.44 156.87 162.32 162.32 1,627,755
Oct 6, 2025 157.98 160.62 156.93 158.28 158.28 1,734,720
Oct 3, 2025 153.00 158.19 151.77 157.16 157.16 3,486,451
Oct 2, 2025 148.70 152.85 145.24 152.80 152.80 2,288,672
Oct 1, 2025 144.70 148.16 143.18 147.28 147.28 2,026,079
Sep 30, 2025 141.63 145.41 141.00 144.01 144.01 2,654,255
Sep 29, 2025 137.19 141.81 136.62 141.65 141.65 2,564,031
Sep 26, 2025 136.86 137.04 134.01 137.03 137.03 1,389,737
Sep 25, 2025 140.55 140.65 135.08 135.59 135.59 2,168,769
Sep 24, 2025 144.97 145.56 140.87 141.00 141.00 1,455,591
Sep 23, 2025 144.71 146.29 143.83 145.38 145.38 1,610,390
Sep 22, 2025 144.76 146.71 144.03 145.03 145.03 2,896,264

Open, high, low and close are the prices as traded. Adjusted close accounts for splits and dividends, and is what the chart and returns use. Where a company changed its ticker, its history under the old symbol is included.

Need daily prices for every ticker, in code?

The Quiver API serves daily prices back to 2014 alongside congressional trades, insider trades, 13F holdings and lobbying, all under one key and inside Claude or ChatGPT through our MCP server.

Explore the Quiver API
Insmed, Inc. Executive Compensation

We estimate that -- received a compensation of -- in --, making them the highest paid executive at INSM, per a recent SEC DEF 14A filing. We estimate that the median employee at INSMED Inc is paid $279,760.



Name
Role
Salary
Bonus
Stock/Option Awards
Total Compensation